Shionogi
Clinical trials sponsored by Shionogi, explained in plain language.
A Japanese pharmaceutical company focused on infectious diseases and pain management.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
ALS drug trial halted: oral Edaravone's promise unfulfilled
Disease control TerminatedThis study tested an oral form of edaravone in 384 adults with ALS to see if it could slow the disease's progression over 48 weeks. Participants were randomly assigned to different dosing schedules. The trial was terminated early, and results are not yet fully available.
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Stroke drug study halted early: new dosing regimen tested in 17 patients
Disease control TerminatedThis study aimed to find the best dose of MCI-186 for people who had an acute ischemic stroke. It compared a new way of giving the drug (a bolus followed by continuous infusion) with the standard twice-daily dosing for 14 days. The trial was terminated early and included only 17 …
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC